A response-guided approach based on HBsAg kinetics may identify patients with the greatest chance of success  by Halfon, Philippe et al.
Letters to the Editor
OpenA response-guided approach based on HBsAg kinetics may
identify patients with the greatest chance of successIn conclusion, based on the Ning et al. study, in our hands and
others, in order to increase the HBsAg clearance rate, we empha-
size the beneﬁts of both the switch to or add-on therapy and
HBsAg monitoring to individualize the treatment and to imple-
ment stopping rules for ending or extending IFN treatment.
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We read with interest the paper by Ning et al. entitled ‘‘Switching
from entecavir to PegIFN alfa-2a in patients with HBeAg-positive
chronic hepatitis B: A randomised open-label trial (OSST trial)’’ in
the latest issue of the Journal of Hepatology [1]. The authors con-
ducted a randomized open study (randomization: 1:1; peginter-
feron alfa-2a 180 lg/week or entecavir [ETV] 0.5 mg/day for
48 weeks) in HBe antigen (HBeAg)-positive CHB patients who
had received ETV for 9–36 months, with HBeAg <100 PEIU/ml
and HBV DNA 61000 copies/ml. The primary end point was
HBeAg seroconversion at week 48.
Their ﬁndings have practical implications on patients receiv-
ing long-term ETV therapy, because they demonstrate that it is
possible to enhance the chances of HBeAg seroconversion and
HBsAg loss by switching to a ﬁnite course of PegIFN alfa-2a ther-
apy. Patients who lose HBeAg and have HBsAg levels <1500 IU/ml
with ETV are recommended to switch to PegIFN because they
have a good chance of HBsAg loss (22.2%) and HBeAg seroconver-
sion (33.3%). Those, who still have HBsAg levels >1500 IU/ml at
week 12 after switching, have a low chance of success (negative
predictive value 98% for HBsAg loss and 95% for HBeAg serocon-
version). These patients should consider stopping PegIFN.
In order to ﬁnd an alternative solution to indeﬁnite nucle-
os(t)ide analogue (NA) therapy, two concepts were developed:
switching or add-on PegIFN alfa-2a. Both signiﬁcantly increased
the rate of HBeAg seroconversion and HBsAg loss. Recently,
Brouwer et al. demonstrated that adding PegIFN to ETV increases
the response rates in HbeAg-positive chronic hepatitis B
patients [2].
A third approach was reported, which suggests that an exten-
sion of 48- to 96-week of PegIFN treatment may improve the
chances of deﬁnite treatment in HBeAg negative chronic hepatitis
B patients treated with NA [3].
We used this third strategy by extending PegIFN up to
96 weeks, which according to the evolution of the HBsAg titre pro-
vided a loss of HBsAg in six out of 10 patients with HBs serocon-
version in two patients, regardless of the HBV genotype or IL28B
status. The HBsAg titre decline constituted a useful tool to predict
the loss of HBsAg and to determine the optimal duration of PegIFN
add-on therapy. This concept of time-individualized therapy,
based on HBsAgmonitoring, was recently demonstrated with suc-
cess in the IFN treatment of chronic hepatitis delta patients [4,5].Journal of Hepatology 2015 vol. 62 j 238–251
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